Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Decision Resources Group
Public Healthcare Systems in Brazil and Mexico Cover Targeted Therapies but with Indication-Specific Restrictions, According to Findings from Decision Resources Group
BURLINGTON, Mass., June 9, 2014 /PRNewswire/ -- Decision Resources Group finds that targeted therapies such as MabThera (rituximab) for non-Hodgkin's lymphoma (NHL) and Velcade (bortezomib) for multiple myeloma (MM) enjoy extensive but incomplete coverage in Brazil and Mexico through complex mechanisms. To obtain reimbursement, novel therapies for these indications must show head-to-head clinical benefits and improved cost-effectiveness (or other pharmacoeconomic benefits such as reduced budgetary impact) against these standards of care. However, meeting these requirements may become increasingly challenging because each of these markets has already welcomed a copy biologic or a generic version of these agents. Nonetheless, as the prevalence of NHL and MM continues to grow with the aging populations of Brazil and Mexico, the need for novel, more tolerable and effective agents increases.
Other key findings from the Emerging Markets Physician and Payer Forum report entitled The Impact of LATAM (Brazil and Mexico) Payer Policy on Prescribing in Non-Hodgkin's Lymphoma and Multiple Myeloma include:
Comments from Decision Resources Group Analyst Solsire Zevallos, Ph.D.:
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
©2012 PR Newswire. All Rights Reserved.